Status:

COMPLETED

Clinical Investigation of a New Version of MAIA Microperimeter on Healthy Subjects and Patients With Retinal Pathology

Lead Sponsor:

Centervue SpA

Conditions:

Healthy Eyes

Retinal Diseases

Eligibility:

All Genders

18-90 years

Phase:

NA

Brief Summary

The purpose of this pre-market, monocentric cross-sectional study is to evaluate the clinical usefulness of a new version of the MAIA device (MAIA) through an agreement with the established version of...

Eligibility Criteria

Inclusion

  • Healthy Subjects
  • Age: 18-90 years old;
  • BCVA ≥ 0.8 Decimal;
  • Equivalent spherical refraction between -12D and +6D; astigmatism within 2D;
  • IOP ≤ 21 mmHg;
  • Clinically normal appearance of the optic nerve head (examined with Spectralis OCT);
  • Clinically normal appearance of the macula (examined with Spectralis OCT);
  • No ocular pathologies, trauma, surgeries;
  • Absence of pathologies that can affect visual field;
  • No use of drugs inferfering with the correct execution of perimetry;

Exclusion

  • Glaucoma or glaucoma suspect diagnosis;
  • IOP ≥ 22 mmHg;
  • Presence or history of disc hemorrhage;
  • Presence of amblyopia;
  • Nystagmus or poor fixation;
  • Previous laser or any ocular surgery, including uncomplicated cataract surgery performed within 6 months before enrollment;
  • Any active infection of anterior or posterior segments;
  • Subjects with significant ocular media opacities;
  • Evidence of diabetic retinopathy, diabetic macular edema, or other retinal disease;
  • Use of any drug that can interfere with the correct execution of microperimetry or that would produce visual field loss;
  • Unable to tolerate ophthalmic imaging;
  • Claustrophobia;
  • Inability to provide informed consent.
  • Patients with retinal pathology
  • Inclusion Criteria:
  • Age: 18-90 years old;
  • BCVA ≥ 0.1 Decimal;
  • Equivalent spherical refraction between -12D and +6D; astigmatism within 2D;
  • Diagnosis of any type of retinal disease by investigator based on fundoscopy and Spectralis OCT for which microperimetry is indicated;

Key Trial Info

Start Date :

October 17 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 12 2024

Estimated Enrollment :

68 Patients enrolled

Trial Details

Trial ID

NCT06071546

Start Date

October 17 2023

End Date

July 12 2024

Last Update

August 13 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Universitätsspital Basel, Augenklinik

Basel, Switzerland, CH-4031